NXP-900

N/A

Report date: 2024/12/19 11:48:54
NME

Base Information

Drug NameNXP-900
Drug Alias NameeCF506NXP-900
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase SRC inhibitorsYes tyrosine protein kinase inhibitors
TargetsTyrosine-protein kinase SRCYes tyrosine protein kinase
Therapy Area/IndicationsSolid tumoursKidney NeoplasmsCarcinoma, Non-Small-Cell Lung +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited Kingdom
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesThe University Of Edinburgh
China Registration ClassN/A

Develop Information

Active CompaniesNuvectis Pharma Inc
Inactive CompaniesThe University Of Edinburgh
Active IndicationsSolid tumoursKidney NeoplasmsCarcinoma, Non-Small-Cell Lung +[5] 
Inactive IndicationsOvarian NeoplasmsBreast NeoplasmsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A